硬皮病的治疗现状与展望  

Scleroderma therapy:a review of recent advances and perspective

作　　者：陈卫[1,2,3] 杨蓉娅[2] 

机构地区：[1]解放军总医院(解放军医学院) [2]北京军区总医院全军皮肤损伤修复研究所 [3]解放军66029部队医院

出　　处：《实用皮肤病学杂志》2015年第5期367-370,共4页Journal of Practical Dermatology

摘　　要：系统性硬皮病(systemic sclerosis,SSc)是一种慢性多系统的结缔组织疾病,其发病机制复杂。目前,尚无一种特效的治疗方法能检测硬皮病的发展,常需要多个临床科室对患者进行综合治疗。近年来,大量的临床研究揭示硬皮病的发病机制涉及多种细胞和分子因素,这就为未来产生新的治疗方法提供了可能。该文主要对目前的治疗方法和最新进展进行综述。这些治疗方法根据他们不同的作用机制,如免疫调节、抗纤维化及血管扩张剂等进行分类,同时对每种治疗方法进行分析讨论。Scleroderma（systemic sclerosis,SSc） is a chronic,multisystem connective tissue disease with a complex pathogenesis. Till now there is no sole therapy with optimal beneficial effects on all aspects of the disease process. It usually requires interdisciplinary approach in individual patient management. Recently,Clinical research to unravel the pathogenesis of scleroderma has implicated multiple cellular and molecular factors that are potential targets for future therapy. The objective of this article is to provide an overview of the available treatments and recent advances in the therapy of Scleroderma. These therapies have been classified into categories according to their mode of action-immunomodulators,antifibrotic or vasodilators and each will be discussed individually.

关 键 词：硬皮病 系统性 治疗 

分 类 号：R593.25[医药卫生—内科学]